Regional Health Properties, Inc.

Regional Health Properties, Inc., through its subsidiaries, operates as a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior living. Its business principally consists of leasing and subleasing such facilities to third-party tenants, which operate the facilities. The company's facilities provide a range of healthcare services to patients and residents, including skilled nursing and assisted living services, social services, various therapy services, and other rehabilitative and healthcare services for long-term and short-stay patients and residents. As of December 31, 2021, it owned, leased, or managed 24 facilities primarily in the Southeastern United States of America. The company was incorporated in 1991 and is headquartered in Suwanee, Georgia.

Regional Health Properties, Inc. trades as RHE on AMEX. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $53,160 of revenue and $3,045 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Regional Health Properties, Inc. can be compared against peers such as BiondVax Pharmaceuticals Ltd., Greenbrook TMS Inc., LumiraDx Limited, ModivCare Inc., NanoString Technologies, Inc., Invitae Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $5.21M, beta of 0.95, and return on equity of +872.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

RHE currently shows total debt of $2,325 and beta of 0.95. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 4 (2026-05-22 00:00:00), 10-Q (2026-05-15 00:00:00), SC 13G/A (2026-05-15 00:00:00), 4 (2026-05-07 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://regionalhealthproperties.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.